These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27450507)

  • 1. Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.
    Beshir SA; Chee KH; Lo YL
    Int J Clin Pharm; 2016 Oct; 38(5):1182-90. PubMed ID: 27450507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Predicted Rate and Associated Factors of Dabigatran-induced Bleeding Events in Malaysian Patients with Non-Valvular Atrial Fibrillation.
    Beshir SA; Yap LB; Sim S; Chee KH; Lo YL
    J Pharm Pharm Sci; 2017; 20(1):365-377. PubMed ID: 29145930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study.
    Pallisgaard JL; Lindhardt TB; Hansen ML; Schjerning AM; Olesen JB; Staerk L; Torp-Pedersen C; Gislason GH
    PLoS One; 2015; 10(10):e0141377. PubMed ID: 26513589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.
    Russo V; Bianchi V; Cavallaro C; Vecchione F; De Vivo S; Santangelo L; Sarubbi B; Calabrò P; Nigro G; D'Onofrio A
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(20):3961-7. PubMed ID: 26531286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
    Avgil Tsadok M; Jackevicius CA; Rahme E; Humphries KH; Pilote L
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):593-9. PubMed ID: 26508666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study.
    Verdecchia P; Vedovati MC; Conti S; Giustozzi M; Aita A; Molini G; Angeli F; Turturiello D; Becattini C; Cavallini C; Agnelli G
    Expert Opin Drug Saf; 2018 Nov; 17(11):1063-1069. PubMed ID: 30260252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation.
    Hernandez I; Zhang Y; Brooks MM; Chin PK; Saba S
    Stroke; 2017 Jan; 48(1):159-166. PubMed ID: 27909200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program.
    Yasaka M; Uchiyama S; Atarashi H; Okumura K; Koretsune Y; Yamashita T; Taniguchi A; Fukaya T; Inoue H;
    J Stroke Cerebrovasc Dis; 2020 May; 29(5):104717. PubMed ID: 32113736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
    Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
    Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.
    Hernandez I; Zhang Y
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):37-47. PubMed ID: 27637493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation.
    Paquette M; Riou França L; Teutsch C; Diener HC; Lu S; Dubner SJ; Ma CS; Rothman KJ; Zint K; Halperin JL; Huisman MV; Lip GYH; Nieuwlaat R
    J Am Coll Cardiol; 2017 Sep; 70(13):1573-1583. PubMed ID: 28935034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care.
    Schneeweiss S; Gopalakrishnan C; Bartels DB; Franklin JM; Zint K; Kulldorff M; Huybrechts KF
    Circ Cardiovasc Qual Outcomes; 2019 Feb; 12(2):e005173. PubMed ID: 30764655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry.
    Vene N; Mavri A; Gubenšek M; Tratar G; Vižintin Cuderman T; Pohar Perme M; Blinc A
    PLoS One; 2016; 11(6):e0156943. PubMed ID: 27280704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry.
    Königsbrügge O; Simon A; Domanovits H; Pabinger I; Ay C
    BMC Cardiovasc Disord; 2016 Dec; 16(1):254. PubMed ID: 27938343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.